Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Combination signal transduction inhibitor therapy

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Melanoma / Systematic Treatment for Unresectable Stage III, Stage IV, and Recurrent Disease / Signal transduction inhibitors

The FDA approved the combination regimens dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib in patients with unresectable or metastatic melanomas that carry BRAF V600E or V600K pathogenic variants as confirmed by an FDA-approved test. The approvals were based on improved PFS and OS when compared with a single-agent BRAF inhibitor (either dabrafenib or vemurafenib).

Preserved source evidence · Not medical advice